organization · Reporting owner

Lux Co-Invest Opportunities, L.P.

Disclosed activity across 5 companies

Tapewire entity: 124766
SEC CIK: 0001722022

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Science 37 Holdings, Inc.SNCE · Entity 15235	10% owner	April 04, 2022	April 06, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Science 37 Holdings, Inc.

Report date April 04, 2022 · Filed April 06, 2022

Jointly reported with Lux Capital Management, LLC, Lux Ventures IV, L.P., Lux Venture Partners IV, LLC, Lux Co-Invest Partners, LLC, Hebert Peter, Wolfe Josh

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Lux Ventures IV, L.P.	8,743,999	Reported balance After 2022-04-04 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2022-04-04 · Other · Disposed 2,914,667 · Balance 8,743,999 F1: Pro rata distribution of 2,914,667 shares from Lux Ventures IV, L.P. to its partners. F2: Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, L.P. and exercises voting and dispositive power over the shares held by Lux Ventures IV, L.P. Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares held by Lux Co-Invest Opportunities, L.P. Peter Hebert and Joshua Wolfe are the individual managers of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC and may be deemed to share voting and dispositive power over the shares held by each of Lux Ventures IV, L.P. and Lux Co-Invest Opportunities, L.P., Lux Capital Management, LLC, as the investment manager for each of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power over the shares held by each of Lux Ventures IV, L.P. and Lux Co-Invest Opportunities, L.P. F3: Each of Lux Capital Management, LLC, Lux Venture Partners IV, LLC, Lux Co-Invest Partners, LLC, Peter Hebert and Joshua Wolfe disclaim beneficial ownership over the shares reported herein except to the extent of their pecuniary interest therein, if any.
Common StockSEC Table I · non-derivative	IndirectBy Lux Co-Invest Opportunities, L.P.	3,505,890	Reported balance Holding disclosure · report date 2022-04-04 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 3,505,890 F2: Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, L.P. and exercises voting and dispositive power over the shares held by Lux Ventures IV, L.P. Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares held by Lux Co-Invest Opportunities, L.P. Peter Hebert and Joshua Wolfe are the individual managers of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC and may be deemed to share voting and dispositive power over the shares held by each of Lux Ventures IV, L.P. and Lux Co-Invest Opportunities, L.P., Lux Capital Management, LLC, as the investment manager for each of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power over the shares held by each of Lux Ventures IV, L.P. and Lux Co-Invest Opportunities, L.P. F3: Each of Lux Capital Management, LLC, Lux Venture Partners IV, LLC, Lux Co-Invest Partners, LLC, Peter Hebert and Joshua Wolfe disclaim beneficial ownership over the shares reported herein except to the extent of their pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: Pro rata distribution of 2,914,667 shares from Lux Ventures IV, L.P. to its partners.

F2: Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, L.P. and exercises voting and dispositive power over the shares held by Lux Ventures IV, L.P. Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares held by Lux Co-Invest Opportunities, L.P. Peter Hebert and Joshua Wolfe are the individual managers of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC and may be deemed to share voting and dispositive power over the shares held by each of Lux Ventures IV, L.P. and Lux Co-Invest Opportunities, L.P., Lux Capital Management, LLC, as the investment manager for each of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power over the shares held by each of Lux Ventures IV, L.P. and Lux Co-Invest Opportunities, L.P.

F3: Each of Lux Capital Management, LLC, Lux Venture Partners IV, LLC, Lux Co-Invest Partners, LLC, Peter Hebert and Joshua Wolfe disclaim beneficial ownership over the shares reported herein except to the extent of their pecuniary interest therein, if any.

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Aeva Technologies, Inc.

Report date August 05, 2022 · Filed August 09, 2022

Jointly reported with Hebert Peter, Wolfe Josh, Lux Ventures IV, L.P., Lux Venture Partners IV, LLC, Lux Co-Invest Partners, LLC

Section 16 reporting ended · disclosed 2022-08-09. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	14,692,316	Reported balance After 2022-08-05 transaction · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · 2022-08-05 · Other · Disposed 7,346,159 · Balance 14,692,316 F1: Pro rata distribution from Lux Ventures IV, L.P. to its partners. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC (the "Individual Lux Managers"). The Individual Lux Managers, as the sole managers of Lux Venture Partners IV, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. Each of Lux Venture Partners IV, LLC and the Individual Lux Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,959,371	Reported balance Holding disclosure · report date 2022-08-05 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 1,959,371 F2: These shares are owned directly by Lux Co-Invest Opportunities, L.P. Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Co-Invest Opportunities, L.P. The Individual Lux Managers are the individual managing members of Lux Co-Invest Partners, LLC. The Individual Lux Managers, as the sole managers of Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Co-Invest Opportunities, L.P. Each of Lux Co-Invest Partners, LLC and the Individual Lux Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest.

Filing footnotes · ownership attribution and instrument terms

F1: Pro rata distribution from Lux Ventures IV, L.P. to its partners. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC (the "Individual Lux Managers"). The Individual Lux Managers, as the sole managers of Lux Venture Partners IV, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. Each of Lux Venture Partners IV, LLC and the Individual Lux Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein.

F2: These shares are owned directly by Lux Co-Invest Opportunities, L.P. Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Co-Invest Opportunities, L.P. The Individual Lux Managers are the individual managing members of Lux Co-Invest Partners, LLC. The Individual Lux Managers, as the sole managers of Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Co-Invest Opportunities, L.P. Each of Lux Co-Invest Partners, LLC and the Individual Lux Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest.

Latch, Inc.

Report date September 28, 2021 · Filed October 05, 2021

Jointly reported with Lux Ventures IV, L.P., Lux Venture Partners IV, LLC, Lux Co-Invest Partners, LLC, Hebert Peter, Wolfe Josh

Section 16 reporting ended · disclosed 2021-10-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	7,228,469	Reported balance After 2021-09-28 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2021-09-28 · Other · Disposed 2,409,489 · Balance 7,228,469 F1: Pro rata distribution from Lux Ventures IV, L.P. to its partners. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC (the "Individual Lux Managers"). The Individual Lux Managers, as the sole managers of Lux Venture Partners IV, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. Each of Lux Venture Partners IV, LLC and the Individual Lux Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	4,084,493	Reported balance After 2021-09-28 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2021-09-28 · Other · Disposed 1,358,164 · Balance 4,084,493 F2: Pro rata distribution from Lux Co-Invest Opportunities, L.P. to its partners. Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Co-Invest Opportunities, L.P. The Individual Lux Managers are the individual managing members of Lux Co-Invest Partners, LLC. The Individual Lux Managers, as the sole managers of Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Co-Invest Opportunities, L.P. Each of Lux Co-Invest Partners, LLC and the Individual Lux Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest.

Filing footnotes · ownership attribution and instrument terms

F2: Pro rata distribution from Lux Co-Invest Opportunities, L.P. to its partners. Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Co-Invest Opportunities, L.P. The Individual Lux Managers are the individual managing members of Lux Co-Invest Partners, LLC. The Individual Lux Managers, as the sole managers of Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Co-Invest Opportunities, L.P. Each of Lux Co-Invest Partners, LLC and the Individual Lux Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest.

Matterport, Inc./DE

Report date January 18, 2022 · Filed January 21, 2022

Jointly reported with Hebert Peter, Wolfe Josh, Lux Ventures III, L.P., Lux Ventures III Special Founders Fund, L.P., Lux Ventures Cayman III, L.P.

Section 16 reporting ended · disclosed 2022-01-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	IndirectSee Footnote	18,919,230	Reported balance After 2022-01-18 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2022-01-18 · Other · Disposed 6,306,411 · Balance 18,919,230 F1: Pro rata distribution of (i) 4,406,063 shares from Lux Ventures III, L.P. to its partners, (ii) 2,168 shares from Lux Ventures Special Founders Fund, L.P. to its partners, (iii) 209,042 shares from Lux Ventures Cayman III, L.P. to its partners, and (iv) 1,689,138 shares from Lux Co-Invest Opportunities, L.P. to its partners. Lux Venture Partners III, LLC is the general partner of each of Lux Ventures III L.P. and Lux Ventures III Special Founders Fund, L.P. and exercises voting and dispositive power over the shares held thereby. Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Co-Invest Opportunities, L.P. Lux Ventures Cayman III General Partner Limited is the general partner of Lux Ventures Cayman III, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Ventures Cayman III, L.P. F2: (continued from footnote 1) Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners III, LLC, Lux Co-Invest Partners, LLC and Lux Ventures Cayman III General Partner Limited. The individual managers, as the sole managers of Lux Venture Partners III, LLC, Lux Co-Invest Partners, LLC and Lux Ventures Cayman III General Partner Limited, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures III, L.P., Lux Co-Invest Opportunities, L.P., Lux Ventures Cayman III, L.P. and Lux Ventures III Special Founders Fund, L.P. Each of Lux Venture Partners III, LLC, Lux Co-Invest Partners, LLC and Lux Ventures Cayman III General Partner Limited, and the individual managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Pro rata distribution of (i) 4,406,063 shares from Lux Ventures III, L.P. to its partners, (ii) 2,168 shares from Lux Ventures Special Founders Fund, L.P. to its partners, (iii) 209,042 shares from Lux Ventures Cayman III, L.P. to its partners, and (iv) 1,689,138 shares from Lux Co-Invest Opportunities, L.P. to its partners. Lux Venture Partners III, LLC is the general partner of each of Lux Ventures III L.P. and Lux Ventures III Special Founders Fund, L.P. and exercises voting and dispositive power over the shares held thereby. Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Co-Invest Opportunities, L.P. Lux Ventures Cayman III General Partner Limited is the general partner of Lux Ventures Cayman III, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Ventures Cayman III, L.P.

F2: (continued from footnote 1) Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners III, LLC, Lux Co-Invest Partners, LLC and Lux Ventures Cayman III General Partner Limited. The individual managers, as the sole managers of Lux Venture Partners III, LLC, Lux Co-Invest Partners, LLC and Lux Ventures Cayman III General Partner Limited, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures III, L.P., Lux Co-Invest Opportunities, L.P., Lux Ventures Cayman III, L.P. and Lux Ventures III Special Founders Fund, L.P. Each of Lux Venture Partners III, LLC, Lux Co-Invest Partners, LLC and Lux Ventures Cayman III General Partner Limited, and the individual managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein.

RECURSION PHARMACEUTICALS, INC.

Report date December 07, 2021 · Filed December 09, 2021

Jointly reported with Lux Ventures IV, L.P., Lux Venture Partners IV, LLC, Lux Co-Invest Partners, LLC, Hebert Peter, Wolfe Josh

Section 16 reporting ended · disclosed 2021-12-09. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A common stockSEC Table I · non-derivative	Direct	13,021,519	Reported balance After 2021-12-07 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2021-12-07 · Other · Disposed 4,265,576 · Balance 13,021,519 F1: Pro rata distribution from Lux Ventures IV, L.P. to its partners. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC (the "Individual Lux Managers"). The Individual Lux Managers, as the sole managers of Lux Venture Partners IV, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. Each of Lux Venture Partners IV, LLC and the Individual Lux Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 05, 2022 Filed Aug 9, 2022 17:01 UTC	Aeva Technologies, Inc. AEVA · Entity 4949	OtherCommon Stock	7,346,159	$0.00	$0.00	Disclosure SEC source: 0001493152-22-021786 · ownership.xml · nonDerivative · entry 1 Hebert Peter · CIK 0001683771 · 10% owner Wolfe Josh · CIK 0001830001 · 10% owner Lux Ventures IV, L.P. · CIK 0001633331 · 10% owner Lux Co-Invest Opportunities, L.P. · CIK 0001722022 · 10% owner Lux Venture Partners IV, LLC · CIK 0001633332 · 10% owner Lux Co-Invest Partners, LLC · CIK 0001722021 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 14,692,316 F1 · kind: Pro rata distribution from Lux Ventures IV, L.P. to its partners. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC (the "Individual Lux Managers"). The Individual Lux Managers, as the sole managers of Lux Venture Partners IV, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. Each of Lux Venture Partners IV, LLC and the Individual Lux Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein. F1 · ownership.nature: Pro rata distribution from Lux Ventures IV, L.P. to its partners. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC (the "Individual Lux Managers"). The Individual Lux Managers, as the sole managers of Lux Venture Partners IV, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. Each of Lux Venture Partners IV, LLC and the Individual Lux Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein. Read SEC document
April 04, 2022 Filed Apr 6, 2022 20:43 UTC	Science 37 Holdings, Inc. SNCE · Entity 15235	OtherCommon Stock	2,914,667	$0.00	$0.00	Disclosure SEC source: 0000905718-22-000545 · science_fm4apr42022.xml · nonDerivative · entry 1 Lux Capital Management, LLC · CIK 0001592843 · 10% owner Lux Ventures IV, L.P. · CIK 0001633331 · 10% owner Lux Venture Partners IV, LLC · CIK 0001633332 · 10% owner Lux Co-Invest Opportunities, L.P. · CIK 0001722022 · 10% owner Lux Co-Invest Partners, LLC · CIK 0001722021 · 10% owner Hebert Peter · CIK 0001683771 · 10% owner Wolfe Josh · CIK 0001830001 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Lux Ventures IV, L.P. Disclosed balance after: 8,743,999 F1 · kind: Pro rata distribution of 2,914,667 shares from Lux Ventures IV, L.P. to its partners. F2 · ownership.nature: Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, L.P. and exercises voting and dispositive power over the shares held by Lux Ventures IV, L.P. Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares held by Lux Co-Invest Opportunities, L.P. Peter Hebert and Joshua Wolfe are the individual managers of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC and may be deemed to share voting and dispositive power over the shares held by each of Lux Ventures IV, L.P. and Lux Co-Invest Opportunities, L.P., Lux Capital Management, LLC, as the investment manager for each of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power over the shares held by each of Lux Ventures IV, L.P. and Lux Co-Invest Opportunities, L.P. F3 · ownership.nature: Each of Lux Capital Management, LLC, Lux Venture Partners IV, LLC, Lux Co-Invest Partners, LLC, Peter Hebert and Joshua Wolfe disclaim beneficial ownership over the shares reported herein except to the extent of their pecuniary interest therein, if any. Read SEC document
January 18, 2022 Filed Jan 21, 2022 07:16 UTC	Matterport, Inc./DE MTTR · Entity 82549	OtherClass A Common Stock	6,306,411	$0.00	$0.00	Disclosure SEC source: 0000905718-22-000125 · matterport_fm4jan182022.xml · nonDerivative · entry 1 Hebert Peter · CIK 0001683771 · 10% owner Wolfe Josh · CIK 0001830001 · 10% owner Lux Ventures III, L.P. · CIK 0001534238 · 10% owner Lux Ventures III Special Founders Fund, L.P. · CIK 0001534241 · 10% owner Lux Ventures Cayman III, L.P. · CIK 0001569760 · 10% owner Lux Co-Invest Opportunities, L.P. · CIK 0001722022 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 18,919,230 F1 · kind: Pro rata distribution of (i) 4,406,063 shares from Lux Ventures III, L.P. to its partners, (ii) 2,168 shares from Lux Ventures Special Founders Fund, L.P. to its partners, (iii) 209,042 shares from Lux Ventures Cayman III, L.P. to its partners, and (iv) 1,689,138 shares from Lux Co-Invest Opportunities, L.P. to its partners. Lux Venture Partners III, LLC is the general partner of each of Lux Ventures III L.P. and Lux Ventures III Special Founders Fund, L.P. and exercises voting and dispositive power over the shares held thereby. Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Co-Invest Opportunities, L.P. Lux Ventures Cayman III General Partner Limited is the general partner of Lux Ventures Cayman III, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Ventures Cayman III, L.P. F2 · kind: (continued from footnote 1) Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners III, LLC, Lux Co-Invest Partners, LLC and Lux Ventures Cayman III General Partner Limited. The individual managers, as the sole managers of Lux Venture Partners III, LLC, Lux Co-Invest Partners, LLC and Lux Ventures Cayman III General Partner Limited, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures III, L.P., Lux Co-Invest Opportunities, L.P., Lux Ventures Cayman III, L.P. and Lux Ventures III Special Founders Fund, L.P. Each of Lux Venture Partners III, LLC, Lux Co-Invest Partners, LLC and Lux Ventures Cayman III General Partner Limited, and the individual managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein. F1 · ownership.nature: Pro rata distribution of (i) 4,406,063 shares from Lux Ventures III, L.P. to its partners, (ii) 2,168 shares from Lux Ventures Special Founders Fund, L.P. to its partners, (iii) 209,042 shares from Lux Ventures Cayman III, L.P. to its partners, and (iv) 1,689,138 shares from Lux Co-Invest Opportunities, L.P. to its partners. Lux Venture Partners III, LLC is the general partner of each of Lux Ventures III L.P. and Lux Ventures III Special Founders Fund, L.P. and exercises voting and dispositive power over the shares held thereby. Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Co-Invest Opportunities, L.P. Lux Ventures Cayman III General Partner Limited is the general partner of Lux Ventures Cayman III, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Ventures Cayman III, L.P. F2 · ownership.nature: (continued from footnote 1) Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners III, LLC, Lux Co-Invest Partners, LLC and Lux Ventures Cayman III General Partner Limited. The individual managers, as the sole managers of Lux Venture Partners III, LLC, Lux Co-Invest Partners, LLC and Lux Ventures Cayman III General Partner Limited, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures III, L.P., Lux Co-Invest Opportunities, L.P., Lux Ventures Cayman III, L.P. and Lux Ventures III Special Founders Fund, L.P. Each of Lux Venture Partners III, LLC, Lux Co-Invest Partners, LLC and Lux Ventures Cayman III General Partner Limited, and the individual managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein. Read SEC document
December 07, 2021 Filed Dec 9, 2021 20:57 UTC	RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008	OtherClass A common stock	4,265,576	$0.00	$0.00	Disclosure SEC source: 0000905718-21-001582 · recursion_fm4dec72021.xml · nonDerivative · entry 1 Lux Ventures IV, L.P. · CIK 0001633331 · Former 10% Owner Lux Venture Partners IV, LLC · CIK 0001633332 · Former 10% Owner Lux Co-Invest Opportunities, L.P. · CIK 0001722022 · Former 10% Owner Lux Co-Invest Partners, LLC · CIK 0001722021 · Former 10% Owner Hebert Peter · CIK 0001683771 · Former 10% Owner Wolfe Josh · CIK 0001830001 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,021,519 F1 · kind: Pro rata distribution from Lux Ventures IV, L.P. to its partners. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC (the "Individual Lux Managers"). The Individual Lux Managers, as the sole managers of Lux Venture Partners IV, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. Each of Lux Venture Partners IV, LLC and the Individual Lux Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein. F1 · ownership.direct: Pro rata distribution from Lux Ventures IV, L.P. to its partners. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC (the "Individual Lux Managers"). The Individual Lux Managers, as the sole managers of Lux Venture Partners IV, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. Each of Lux Venture Partners IV, LLC and the Individual Lux Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein. Read SEC document
September 28, 2021 Filed Oct 5, 2021 16:31 UTC	Latch, Inc. LTCH · Entity 9606	OtherCommon Stock	1,358,164	$0.00	$0.00	Disclosure SEC source: 0000905718-21-001276 · latch_fm4sep282021.xml · nonDerivative · entry 2 Lux Ventures IV, L.P. · CIK 0001633331 · 10% owner Lux Venture Partners IV, LLC · CIK 0001633332 · 10% owner Lux Co-Invest Opportunities, L.P. · CIK 0001722022 · 10% owner Lux Co-Invest Partners, LLC · CIK 0001722021 · 10% owner Hebert Peter · CIK 0001683771 · 10% owner Wolfe Josh · CIK 0001830001 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,084,493 F2 · kind: Pro rata distribution from Lux Co-Invest Opportunities, L.P. to its partners. Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Co-Invest Opportunities, L.P. The Individual Lux Managers are the individual managing members of Lux Co-Invest Partners, LLC. The Individual Lux Managers, as the sole managers of Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Co-Invest Opportunities, L.P. Each of Lux Co-Invest Partners, LLC and the Individual Lux Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest. F2 · ownership.nature: Pro rata distribution from Lux Co-Invest Opportunities, L.P. to its partners. Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Co-Invest Opportunities, L.P. The Individual Lux Managers are the individual managing members of Lux Co-Invest Partners, LLC. The Individual Lux Managers, as the sole managers of Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Co-Invest Opportunities, L.P. Each of Lux Co-Invest Partners, LLC and the Individual Lux Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest. Read SEC document
September 28, 2021 Filed Oct 5, 2021 16:31 UTC	Latch, Inc. LTCH · Entity 9606	OtherCommon Stock	2,409,489	$0.00	$0.00	Disclosure SEC source: 0000905718-21-001276 · latch_fm4sep282021.xml · nonDerivative · entry 1 Lux Ventures IV, L.P. · CIK 0001633331 · 10% owner Lux Venture Partners IV, LLC · CIK 0001633332 · 10% owner Lux Co-Invest Opportunities, L.P. · CIK 0001722022 · 10% owner Lux Co-Invest Partners, LLC · CIK 0001722021 · 10% owner Hebert Peter · CIK 0001683771 · 10% owner Wolfe Josh · CIK 0001830001 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,228,469 F1 · kind: Pro rata distribution from Lux Ventures IV, L.P. to its partners. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC (the "Individual Lux Managers"). The Individual Lux Managers, as the sole managers of Lux Venture Partners IV, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. Each of Lux Venture Partners IV, LLC and the Individual Lux Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein. F1 · ownership.nature: Pro rata distribution from Lux Ventures IV, L.P. to its partners. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC (the "Individual Lux Managers"). The Individual Lux Managers, as the sole managers of Lux Venture Partners IV, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. Each of Lux Venture Partners IV, LLC and the Individual Lux Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein. Read SEC document
September 08, 2021 Filed Sep 10, 2021 16:56 UTC	Aeva Technologies, Inc. AEVA · Entity 4949	OtherCommon Stock	7,346,159	$0.00	$0.00	Disclosure SEC source: 0000905718-21-001184 · aevatech_fm4sep82021.xml · nonDerivative · entry 1 Hebert Peter · CIK 0001683771 · 10% owner Wolfe Josh · CIK 0001830001 · 10% owner Lux Ventures IV, L.P. · CIK 0001633331 · 10% owner Lux Co-Invest Opportunities, L.P. · CIK 0001722022 · 10% owner Lux Venture Partners IV, LLC · CIK 0001633332 · 10% owner Lux Co-Invest Partners, LLC · CIK 0001722021 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 22,038,475 F1 · kind: Pro rata distribution from Lux Ventures IV, L.P. to its partners. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC (the "Individual Lux Managers"). The Individual Lux Managers, as the sole managers of Lux Venture Partners IV, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. Each of Lux Venture Partners IV, LLC and the Individual Lux Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein. F1 · ownership.nature: Pro rata distribution from Lux Ventures IV, L.P. to its partners. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC (the "Individual Lux Managers"). The Individual Lux Managers, as the sole managers of Lux Venture Partners IV, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. Each of Lux Venture Partners IV, LLC and the Individual Lux Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein. Read SEC document
April 20, 2021 Filed Apr 20, 2021 21:30 UTC	RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008	ConversionSeries D Preferred Stock · Derivative	1,490,783	$0.00	$0.00	Disclosure SEC source: 0001209191-21-027701 · doc4.xml · derivative · entry 8 Lux Ventures IV, L.P. · CIK 0001633331 · 10% owner Lux Co-Invest Opportunities, L.P. · CIK 0001722022 · 10% owner Lux Co-Invest Partners, LLC · CIK 0001722021 · 10% owner Lux Venture Partners IV, LLC · CIK 0001633332 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,490,783 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date. F10 · shares: Represents 298,156 shares held of record by Lux Ventures IV, L.P. and 1,192,627 shares held of record by Lux Co-Invest Opportunities, L.P. F5 · derivative.exercise_date: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date. F5 · derivative.expiration_date: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date. F5 · derivative.underlying: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date. F10 · derivative.underlying_shares: Represents 298,156 shares held of record by Lux Ventures IV, L.P. and 1,192,627 shares held of record by Lux Co-Invest Opportunities, L.P. F2 · ownership.nature: Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Co-Invest Opportunities, L.P. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, LP and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, or the Individual Managers. The Individual Managers, as the sole managers of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. and Lux Co-Invest Opportunities, L.P. F3 · ownership.nature: Each of Lux Venture Partners IV, LLC, Lux Co-Invest Partners, LLC, and the Individual Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein. Read SEC document
April 20, 2021 Filed Apr 20, 2021 21:30 UTC	RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008	ConversionSeries C Preferred Stock · Derivative	1,825,883	$0.00	$0.00	Disclosure SEC source: 0001209191-21-027701 · doc4.xml · derivative · entry 7 Lux Ventures IV, L.P. · CIK 0001633331 · 10% owner Lux Co-Invest Opportunities, L.P. · CIK 0001722022 · 10% owner Lux Co-Invest Partners, LLC · CIK 0001722021 · 10% owner Lux Venture Partners IV, LLC · CIK 0001633332 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,825,883 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date. F9 · shares: Represents shares held of record by Lux Co-Invest Opportunities, L.P. F5 · derivative.exercise_date: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date. F5 · derivative.expiration_date: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date. F5 · derivative.underlying: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date. F9 · derivative.underlying_shares: Represents shares held of record by Lux Co-Invest Opportunities, L.P. F2 · ownership.nature: Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Co-Invest Opportunities, L.P. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, LP and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, or the Individual Managers. The Individual Managers, as the sole managers of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. and Lux Co-Invest Opportunities, L.P. F3 · ownership.nature: Each of Lux Venture Partners IV, LLC, Lux Co-Invest Partners, LLC, and the Individual Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein. Read SEC document
April 20, 2021 Filed Apr 20, 2021 21:30 UTC	RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008	ConversionSeries B Preferred Stock · Derivative	3,578,653	$0.00	$0.00	Disclosure SEC source: 0001209191-21-027701 · doc4.xml · derivative · entry 6 Lux Ventures IV, L.P. · CIK 0001633331 · 10% owner Lux Co-Invest Opportunities, L.P. · CIK 0001722022 · 10% owner Lux Co-Invest Partners, LLC · CIK 0001722021 · 10% owner Lux Venture Partners IV, LLC · CIK 0001633332 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 3,578,653 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date. F8 · shares: Represents shares held of record by Lux Ventures IV, L.P. F5 · derivative.exercise_date: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date. F5 · derivative.expiration_date: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date. F5 · derivative.underlying: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date. F8 · derivative.underlying_shares: Represents shares held of record by Lux Ventures IV, L.P. F2 · ownership.nature: Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Co-Invest Opportunities, L.P. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, LP and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, or the Individual Managers. The Individual Managers, as the sole managers of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. and Lux Co-Invest Opportunities, L.P. F3 · ownership.nature: Each of Lux Venture Partners IV, LLC, Lux Co-Invest Partners, LLC, and the Individual Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein. Read SEC document
April 20, 2021 Filed Apr 20, 2021 21:30 UTC	RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008	ConversionSeries A Preferred Stock · Derivative	10,279,275	$0.00	$0.00	Disclosure SEC source: 0001209191-21-027701 · doc4.xml · derivative · entry 5 Lux Ventures IV, L.P. · CIK 0001633331 · 10% owner Lux Co-Invest Opportunities, L.P. · CIK 0001722022 · 10% owner Lux Co-Invest Partners, LLC · CIK 0001722021 · 10% owner Lux Venture Partners IV, LLC · CIK 0001633332 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 10,279,275 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date. F8 · shares: Represents shares held of record by Lux Ventures IV, L.P. F5 · derivative.exercise_date: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date. F5 · derivative.expiration_date: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date. F5 · derivative.underlying: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date. F8 · derivative.underlying_shares: Represents shares held of record by Lux Ventures IV, L.P. F2 · ownership.nature: Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Co-Invest Opportunities, L.P. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, LP and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, or the Individual Managers. The Individual Managers, as the sole managers of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. and Lux Co-Invest Opportunities, L.P. F3 · ownership.nature: Each of Lux Venture Partners IV, LLC, Lux Co-Invest Partners, LLC, and the Individual Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein. Read SEC document
April 20, 2021 Filed Apr 20, 2021 21:30 UTC	RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008	ConversionClass A Common Stock	17,187,095	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-027701 · doc4.xml · nonDerivative · entry 4 Lux Ventures IV, L.P. · CIK 0001633331 · 10% owner Lux Co-Invest Opportunities, L.P. · CIK 0001722022 · 10% owner Lux Co-Invest Partners, LLC · CIK 0001722021 · 10% owner Lux Venture Partners IV, LLC · CIK 0001633332 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 17,287,095 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · shares: 3,068,510 of these shares are held by Lux Co-Invest Opportunities, L.P. and 14,206,084 of these shares are held by Lux Ventures IV, L.P. F7 · price: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. F6 · balance_after: 3,068,510 of these shares are held by Lux Co-Invest Opportunities, L.P. and 14,206,084 of these shares are held by Lux Ventures IV, L.P. F2 · ownership.nature: Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Co-Invest Opportunities, L.P. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, LP and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, or the Individual Managers. The Individual Managers, as the sole managers of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. and Lux Co-Invest Opportunities, L.P. Read SEC document
April 20, 2021 Filed Apr 20, 2021 21:30 UTC	RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008	ConversionCommon Stock	17,187,095	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-027701 · doc4.xml · nonDerivative · entry 3 Lux Ventures IV, L.P. · CIK 0001633331 · 10% owner Lux Co-Invest Opportunities, L.P. · CIK 0001722022 · 10% owner Lux Co-Invest Partners, LLC · CIK 0001722021 · 10% owner Lux Venture Partners IV, LLC · CIK 0001633332 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · shares: 3,068,510 of these shares are held by Lux Co-Invest Opportunities, L.P. and 14,206,084 of these shares are held by Lux Ventures IV, L.P. F7 · price: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. F2 · ownership.nature: Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Co-Invest Opportunities, L.P. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, LP and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, or the Individual Managers. The Individual Managers, as the sole managers of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. and Lux Co-Invest Opportunities, L.P. Read SEC document
April 20, 2021 Filed Apr 20, 2021 21:30 UTC	RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008	ConversionCommon Stock	17,174,594	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-027701 · doc4.xml · nonDerivative · entry 2 Lux Ventures IV, L.P. · CIK 0001633331 · 10% owner Lux Co-Invest Opportunities, L.P. · CIK 0001722022 · 10% owner Lux Co-Invest Partners, LLC · CIK 0001722021 · 10% owner Lux Venture Partners IV, LLC · CIK 0001633332 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 17,187,095 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: 3,018,510 of these shares are held by Lux Co-Invest Opportunities, L.P. and 14,156,084 of these shares are held by Lux Ventures IV, L.P. F5 · price: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date. F6 · balance_after: 3,068,510 of these shares are held by Lux Co-Invest Opportunities, L.P. and 14,206,084 of these shares are held by Lux Ventures IV, L.P. F2 · ownership.nature: Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Co-Invest Opportunities, L.P. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, LP and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, or the Individual Managers. The Individual Managers, as the sole managers of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. and Lux Co-Invest Opportunities, L.P. Read SEC document
April 16, 2021 Filed Apr 20, 2021 21:30 UTC	RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008	PurchaseClass A Common Stock	100,000	$18.00	$1,800,000.00	Disclosure SEC source: 0001209191-21-027701 · doc4.xml · nonDerivative · entry 1 Lux Ventures IV, L.P. · CIK 0001633331 · 10% owner Lux Co-Invest Opportunities, L.P. · CIK 0001722022 · 10% owner Lux Co-Invest Partners, LLC · CIK 0001722021 · 10% owner Lux Venture Partners IV, LLC · CIK 0001633332 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 100,000 F1 · balance_after: 50,000 of these shares are held by Lux Co-Invest Opportunities, L.P. and 50,000 of these shares are held by Lux Ventures IV, L.P. F2 · ownership.nature: Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Co-Invest Opportunities, L.P. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, LP and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, or the Individual Managers. The Individual Managers, as the sole managers of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. and Lux Co-Invest Opportunities, L.P. F3 · ownership.nature: Each of Lux Venture Partners IV, LLC, Lux Co-Invest Partners, LLC, and the Individual Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.